Merck Reports Three-Year KEYNOTE-826 Data for Keytruda in Cervical Cancer

Merck today presented three-year overall survival data from the Phase 3 KEYNOTE-826 trial evaluating Keytruda (pembrolizumab) plus chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer. The data showed a median overall survival of 26.4 months in the Keytruda arm compared to 16.8 months in the placebo arm.